| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QQQ US 11/18/16 P113 | 9 | Q3 2016 | 49.0% |
| ALBANY MOLECULAR RESH INC | 7 | Q2 2016 | 9.4% |
| INFINERA CORPORATION | 7 | Q2 2016 | 12.2% |
| VEREIT Inc Convertible 3% Due 8/1/2018 FA1 | 7 | Q3 2015 | 8.8% |
| Allergan Public Limited Company Preferred | 6 | Q3 2016 | 21.7% |
| VEREIT Inc Convertible 3 3/4% Due 12/15/2020 JD15 | 6 | Q3 2015 | 4.6% |
| Salesforce.com Inc Convertible 0 1/4% Due 4/1/2018 AO1 | 5 | Q3 2016 | 18.7% |
| Palo Alto Networks, Inc 144A Due 7/1/2019 At Mat | 5 | Q3 2016 | 11.1% |
| NXP SEMICONDUCTORS N V | 4 | Q3 2016 | 15.7% |
| PRICELINE GRP INC | 4 | Q4 2015 | 9.6% |
View ALTEGRIS ADVISORS, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-04-02 |
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-09 |
| 13F-NT | 2023-08-10 |
| 13F-NT | 2023-05-09 |
| 13F-NT | 2023-02-15 |
| 13F-NT | 2022-10-28 |
| 13F-NT | 2022-07-26 |
| 13F-NT | 2022-05-11 |
| 13F-NT | 2022-02-04 |
View ALTEGRIS ADVISORS, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.